Sarepta Therapeutics,, Inc. Common Stock

SRPTNASDAQ • USD
ThemeBiotech - Drug Development›Rare Disease Therapeutics
21.36 USD
↗ 0.64 (3.09%)🟢PRE MARKET (AS OF 05:30 AM EDT)
🟢Market: OPEN

SRPT is currently priced at $21.36. The stock presents a mixed profile: our models indicate a Buy for technical indicators, while underlying fundamentals flash a Sell. Notable factors include a concerning Altman Z-Score in the distress zone, negative Return on Equity and a bearish Death Cross on the long-term moving averages. The stock looks compelling on valuation, with multiples below sector averages across P/E, P/B, and EV/EBITDA.

Technical & fundamental data as of Sep 15, 2026.

Open?$20.45
High?$21.36
Low?$20.45
Prev. Close?$20.72
Volume?78
Avg. Volume?3.0M
VWAP?$20.87
Rel. Volume?0.00x
Bid / Ask
Bid?$17.64 × 100
Ask?$24.08 × 100
Spread?$6.44
Midpoint?$20.86
Valuation & Ratios
Market Cap?2.2B
Shares Out?105.6M
Float?98.2M
Float %?93.0%
P/E Ratio?N/A
P/B Ratio?1.43
EPS?-$1.29
Dividend?0.00%
Ex-Dividend?N/A
RelatedEDITCTMX
News
Profile
Sarepta Therapeutics Inc is a commercial-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, gene therapies, and other genetic medicines for rare diseases, particularly neuromuscular disorders. The company has developed approved treatments for Duchenne muscular dystrophy, including EXONDYS 51, VYONDYS 53, AMONDYS 45, and ELEVIDYS, and is advancing additional therapeutic candidates for neuromuscular and other rare diseases. The company operates in one segment: discovering, developing, manufacturing, and delivering therapies to patients with rare diseases.
Themes
Biotech - Drug Development›Rare Disease TherapeuticsHealthcare - Genomics & Precision Medicine›Gene Therapy & Gene Editing
Employees
835
Market Cap
2.2B
Industry
PHARMACEUTICAL PREPARATIONS
Website
www.sarepta.com
Listed
1997-06-04
Address
215 FIRST STREET
CAMBRIDGE, MA 02142
Phone: 617-274-4000
Technical OutlookBuy
Strong SellNeutralStrong Buy
Long-Term (Tide)?▲ Bullish(+1/3)
Medium-Term (Wave)?– Neutral(0/3)
Short-Term (Ripple)?– Neutral(0/3)
MA Alignment?Mixed
Full Technical Analysis →
Fundamental OutlookSell
Strong SellNeutralStrong Buy
F-Score?
23
Z-Score?
2
Momentum?
5
Short Sent.?
21
Piotroski F-Score?3/9Weak
Altman Z-Score?-0.09Distress
Confidence?78%Moderate
Full Fundamental Analysis →
Short InterestSqueeze Risk
Short % of Float?25.07%Squeeze Risk
Short Interest?24.6M
Days to Cover?8.5
Free Float98.2M
Avg Daily Volume2.9M
Settlement Date2026-08-31
Financial Health
Current Ratio?4.42Strong
Quick Ratio?2.62Strong
Cash Ratio?1.14Strong
Debt/Equity?0.55Moderate
ValuationATTRACTIVELY VALUEDvs 2 peers + S&P 500
Score
93/100
P/E?
N/A▾
P/B?
Peers
100
S&P
89
1.43CHEAP▾
P/S?
Peers
100
S&P
85
1.11CHEAP▾
P/FCF?
S&P
36
26.7FAIR▾
EV/EBITDA?
S&P
97
-140.6CHEAP▾
EV/Sales?
Peers
100
S&P
88
1.25CHEAP▾
Returns & Efficiency
ROE?
S&P
10
-9.0%WEAK▾
ROA?
S&P
3
-4.3%WEAK▾
Cash Flow & Enterprise
FCF?$81.8M
Enterprise Value?$2.5B
Fundamentals ratios updated end of day
MarketsMoversWatchlist